- Practice
- About 16 min
- 5 practice questions
Recombinant vaccines and gene therapy
Describe subunit, attenuated and DNA recombinant vaccines, edible vaccines and the recombinant hepatitis B vaccine, and explain gene therapy, its two strategies and two approaches, using ADA deficiency as the case study.
If something looks wrong, please tell us.
By the end of this lesson you can
- Name three types of recombinant vaccine and their advantages.
- Explain how the recombinant hepatitis B vaccine is made.
- Define gene therapy and its augmentation and inhibition strategies.
- Compare somatic cell and germ line gene therapy.
- Describe the first clinical gene therapy, for ADA deficiency.
Recombinant DNA technology changed how we prevent disease (vaccines) and offers a way to treat inherited disease at its root (gene therapy). Both rest on the same idea: put the right gene into the right cell.
Recombinant vaccines
Recombinant vaccines overcome limits of traditional vaccines. They are of uniform quality and cause fewer side effects. Three types are described.
| Type | What it contains | Notes |
|---|---|---|
| Subunit recombinant vaccine | Components of the pathogen (proteins, peptides, DNA), not the whole organism | Pure, stable and safe; example: hepatitis B vaccine |
| Attenuated recombinant vaccine | A pathogen genetically modified to be non-pathogenic | Used as a live vaccine |
| DNA vaccine | A gene for an antigenic protein inserted in a plasmid and taken up by the host's cells | The textbook dates this approach to 1990; cannot cause the disease; easy and cheap to design |
In a DNA vaccine, the cells that take up the plasmid make the antigenic protein and display it on their surface, which triggers an immune response. Because it contains copies of only a few of the pathogen's genes, it cannot cause the disease. New-generation vaccines give long-lasting immunity directed only against the specific pathogen, with less toxicity.
The recombinant hepatitis B vaccine is a subunit vaccine. The gene for the hepatitis B surface antigen (HBsAg) is inserted into a plasmid, and the recombinant DNA is cloned in the yeast Saccharomyces cerevisiae. The yeast cells multiply in a fermentor and make the antigen, which is extracted and purified as the vaccine. Edible vaccines are made by molecular pharming: selected genes are put into plants, and the transgenic plants make the encoded protein. They target mucosal surfaces and stimulate both mucosal and systemic immunity; according to the textbook, edible vaccines for measles, cholera, foot-and-mouth disease and hepatitis were still being tested.
Gene therapy
Gene therapy is the transfer of a normal gene into the cells of a person who carries one or more mutant alleles, so that the normal gene product restores the normal phenotype. The gene is delivered by a vector, often a disabled virus. It aims mainly at single-gene disorders such as cystic fibrosis and haemophilia. Two strategies: gene augmentation therapy inserts DNA to supply a missing gene product; gene inhibition therapy inserts an antisense gene that blocks expression of a harmful dominant gene. Gene therapists must ensure the gene is harmless, is properly expressed, and that the immune system does not attack the new protein.
Two approaches to gene therapy
-
Somatic cell gene therapy
- Gene put into body cells
- Bone marrow, blood or skin cells
- Corrects the disease in the patient
- Not inherited by children
-
Germ line gene therapy
- Gene put into germ cells
- Eggs and sperms
- Change passes to all later generations
- Heritable
Case study: ADA deficiency (SCID)
The first clinical gene therapy was given in 1990 by W. French Anderson to a four-year-old girl with adenosine deaminase (ADA) deficiency. ADA deficiency is an autosomal recessive disorder caused by deletion or malfunction of the ADA gene, and it causes SCID (severe combined immunodeficiency): the T lymphocytes do not work, so the patient cannot fight infections. Some children are helped by bone marrow transplantation from a donor, and some by enzyme replacement therapy, in which working ADA is injected.
Gene therapy for ADA deficiency
- Remove lymphocytes T cells are taken from the patient's blood
- Grow in culture Cells are multiplied in a nutrient medium
- Insert ADA cDNA A disabled retrovirus carries a working ADA gene into the cells
- Check expression Cells are grown to make sure the ADA gene is active
- Return to patient Engineered lymphocytes are infused back and make ADA
Because lymphocytes are not immortal, the patient needs periodic infusions of engineered cells. A permanent cure could come if the ADA gene, isolated from bone marrow cells, were introduced into cells at an early embryonic stage.
Worked reasoning example 1: which strategy?
Disorder X is caused by a recessive allele that makes no enzyme. Disorder Y is caused by a dominant allele that makes a harmful protein. Reasoning: for X, the problem is a missing product, so add a working copy: gene augmentation. For Y, adding a normal copy does not stop the harmful protein, so its expression must be blocked: gene inhibition with an antisense gene.
Worked reasoning example 2: why repeated infusions?
Why did the ADA patient need repeated treatments, and what would make the cure permanent? Reasoning: (1) The corrected cells were mature lymphocytes, which have a limited life span. (2) When they die, new lymphocytes made by the patient's own bone marrow still carry the faulty gene. (3) So engineered cells must be infused again. Permanent fix: correct the cells that keep producing lymphocytes, or the cells of an early embryo, so all their descendants carry the working gene.
Recombinant vaccines: subunit, attenuated, DNA. Gene therapy: augmentation (add) or inhibition (block); somatic (not inherited) or germ line (inherited). First case: ADA-SCID, 1990.
Key takeaways: recombinant vaccines are pure, uniform and safer; the hepatitis B vaccine is a subunit vaccine made in yeast. Gene therapy delivers a normal gene through a vector to correct a genetic defect; somatic changes are not inherited, germ line changes are. ADA deficiency was the first disease treated, using retrovirus-engineered lymphocytes.
Check your understanding
-
1. The first clinical gene therapy was given for the treatment of:
- AIDS
- cancer
- cystic fibrosis
- ADA deficiency (SCID)
Show answer
Answer: D. In 1990 a four-year-old girl with adenosine deaminase deficiency, which causes severe combined immunodeficiency, received the first clinical gene therapy.
-
2. Vaccines that use components of a pathogen rather than the whole organism are called:
- subunit recombinant vaccines
- attenuated recombinant vaccines
- DNA vaccines
- conventional vaccines
Show answer
Answer: A. Subunit vaccines contain parts of the pathogen such as proteins or peptides. Attenuated vaccines contain a whole but harmless organism.
-
3. The recombinant hepatitis B surface antigen gene is cloned for vaccine production in:
- E. coli only
- Saccharomyces cerevisiae
- human lymphocytes
- a retrovirus
Show answer
Answer: B. The HBsAg gene in a plasmid is cloned in yeast, Saccharomyces cerevisiae, which makes the antigen in a fermentor.
-
4. ADA deficiency could be cured permanently by:
- enzyme replacement therapy
- periodic infusion of engineered lymphocytes
- introducing the ADA gene from bone marrow cells into cells at an early embryonic stage
- giving antibiotics
Show answer
Answer: C. Enzyme injections and engineered lymphocytes help only for a time. Correcting cells at an early embryonic stage would pass the working gene to all their descendants, a permanent cure.
-
5. Assertion (A): Somatic cell gene therapy does not affect the patient's children. Reason (R): In somatic cell gene therapy the gene is introduced into body cells, not into eggs or sperms.
- Both A and R are true, and R is the correct explanation of A
- Both A and R are true, but R is not the correct explanation of A
- A is true, but R is false
- A is false, but R is true
Show answer
Answer: A. Only germ cells pass genes to the next generation. Because somatic gene therapy changes body cells only, the change is not inherited. R explains A.
Sign in to keep track of the lessons you finish.